Nasdaq

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

PARSIPPANY, N.J. and REYKJAVÍK, Iceland, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ...
The Victoria Advocate

Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients

INCHEON, South Korea, June 15, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA ® (ustekinumab-stba), a ...
Drug Store News

Teva, Alvotech receive FDA nod for interchangeability of Selardsdi with Stelara

Teva Pharmaceuticals and Alvotech announced that the Food and Drug Administration has approved Selarsdi (ustekinumab-aekn) injection as interchangeable with Stelara (ustekinumab). As of April 30, 2025 ...
JD Supra

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (ustekinumab-aekn) with STELARA (ustekinumab)

On May 5, 2025, Teva and Alvotech announced that the U.S. Food and Drug Administration (FDA) approved SELARSDI (ustekinumab-aekn) injection as an interchangeable biosimilar to the reference product ...